Dr. John A. Ellerton

OptumCare Cancer Care at Fort Apache

Expert in Cancer
Expert in Breast Cancer
134 reported clinical trials
212 drugs studied
4 years of experience

Area of expertise

1Cancer
Global Leader
John A. Ellerton has run 55 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
metastatic
2Breast Cancer
Global Leader
John A. Ellerton has run 25 trials for Breast Cancer. Some of their research focus areas include:
HER2
Stage III
Stage IV

Affiliated Hospitals

Image of trial facility.
OptumCare Cancer Care At Fort Apache
Image of trial facility.
OptumCare Cancer Care At Charleston

Clinical Trials John A. Ellerton is currently running

Image of trial facility.

Surgery and Radiation vs. Radiation Alone

for Brain Cancer

This phase III trial compares the addition of stereotactic radiosurgery before or after surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases.
Recruiting2 awards Phase 3
Image of trial facility.

Fulvestrant + Binimetinib

for Breast Cancer

This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.
Recruiting1 award Phase 219 criteria

More about John A. Ellerton

Clinical Trial Related4 years of experience running clinical trials · Led 134 trials as a Principal Investigator · 75 Active Clinical Trials
Treatments John A. Ellerton has experience with
  • Paclitaxel
  • Nivolumab
  • Carboplatin
  • Fluorouracil
  • Pembrolizumab
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John A. Ellerton specialize in?
John A. Ellerton focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is John A. Ellerton currently recruiting for clinical trials?
Yes, John A. Ellerton is currently recruiting for 68 clinical trials in Las Vegas Nevada. If you're interested in participating, you should apply.
Are there any treatments that John A. Ellerton has studied deeply?
Yes, John A. Ellerton has studied treatments such as Paclitaxel, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with John A. Ellerton?
Apply for one of the trials that John A. Ellerton is conducting.
What is the office address of John A. Ellerton?
The office of John A. Ellerton is located at: OptumCare Cancer Care at Fort Apache, Las Vegas, Nevada 89148 United States. This is the address for their practice at the OptumCare Cancer Care at Fort Apache.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.